<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Молодежный инновационный вестник</journal-id><journal-title-group><journal-title>Молодежный инновационный вестник</journal-title></journal-title-group><issn publication-format="print">2415-7805</issn><publisher><publisher-name>Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Conference Proceedings</subject></subj-group></article-categories><title-group><article-title>Individual approach to the choice of combined oral contraceptives in the treatment of polycystic ovary syndrome: side effects and risks</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chugunova</surname><given-names>Ulyana K.</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>chugunovauluana546@gmail.com</email><uri content-type="orcid">https://orcid.org/0009-0006-4726-198X</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lisitsyna</surname><given-names>Julia D.</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>maxx5000@yandex.ru</email><uri content-type="orcid">https://orcid.org/0009-0000-4528-0470</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kurdeeva</surname><given-names>Polina S.</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>polichkurdeeva@gmail.com</email><uri content-type="orcid">https://orcid.org/0009-0003-0138-6320</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saveleva</surname><given-names>Anastasia A.</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>a.a.savel1999@gmail.com</email><uri content-type="orcid">https://orcid.org/0009-0009-4997-4045</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Glebov</surname><given-names>Sergey G.</given-names></name><bio>&lt;p&gt;Student&lt;/p&gt;</bio><email>Sergey1990Glebov@mail.ru</email><uri content-type="orcid">https://orcid.org/0009-0006-0446-5050</uri><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rusanovsky</surname><given-names>Vladimir V.</given-names></name><bio>&lt;p&gt;Dr. Sci. (Med.) Professor of the Department of Pharmacology with a course of clinical pharmacology and pharmacoeconomics&lt;/p&gt;</bio><email>rusvv2058@mail.ru</email><uri content-type="orcid">https://orcid.org/0000-0002-0432-7946</uri><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">St. Petersburg State Pediatric Medical University</aff><pub-date date-type="epub" iso-8601-date="2025-04-25" publication-format="electronic"><day>25</day><month>04</month><year>2025</year></pub-date><volume>14</volume><issue>S1</issue><fpage>402</fpage><lpage>404</lpage><history><pub-date date-type="received" iso-8601-date="2025-03-09"><day>09</day><month>03</month><year>2025</year></pub-date><pub-date date-type="accepted" iso-8601-date="2025-04-02"><day>02</day><month>04</month><year>2025</year></pub-date></history><permissions><copyright-statement>Copyright © 2025, Chugunova U.K., Lisitsyna J.D., Kurdeeva P.S., Saveleva A.A., Glebov S.G., Rusanovsky V.V.</copyright-statement><copyright-year>2025</copyright-year></permissions><abstract>&lt;p&gt;Combined oral contraceptives (COCs) are the drugs of choice as a contraceptive method in the modern world. However, the prescription of COCs may be based on a number of reasons. It is known that one of the most common is polycystic ovary syndrome (PCOS). Estrogens and their receptors have different cellular and tissue-specific effects, which causes different results of estrogen therapy and side effects on other body systems. Objective. To analyze the frequency of detection of side effects of combined oral contraceptives in the treatment of PCOS. Materials and methods. Search and analysis of literary sources on the Elibrary, PubMed, CyberLeninka, Scopus platforms. Results. We found that when choosing PCOS therapy, along with the restoration of reproductive function, it is necessary to carry out measures aimed at preventing metabolic syndrome and hyperplastic processes in the endometrium. When assessing the safety of using COCs in PCOS, it is necessary to take into account the risks of developing cardiovascular catastrophes. There is no convincing evidence to justify not using COCs in patients with PCOS with metabolic disorders. It is important not only to follow lifestyle modification recommendations for all women with PCOS, but also to perform diagnostic measures before and after prescribing COCs. Conclusion. It is important to note that side effects depend not only on the dose of the drug, but also on hereditary factors and concomitant diseases. That is why COCs are the first-line drugs of choice for achieving the goals of regulating menstruation and improving the symptoms of hyperandrogenism.&lt;/p&gt;</abstract><kwd-group xml:lang="en"><kwd>combined oral contraceptives</kwd><kwd>side effects of oral contraceptives</kwd><kwd>polycystic ovary syndrome</kwd><kwd>gestagens</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>комбинированные оральные контрацептивы</kwd><kwd>побочные эффекты оральных контрацептивов</kwd><kwd>синдром поликистозных яичников</kwd><kwd>гестагены</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Унанян А.Л., Сидорова И.С.,  Коган Е. А. at al / Эстрогены и комбинированные оральные контрацептивы // Вопросы гинекологии, акушерства и перинатологии. – 2020. – Т. 19, № 2. – С. 118-123. – DOI 10.20953/1726-1678-2020-2-118-123.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>И.С., Коган Е.А., Пивазян Л.Г., Ищенко А.И. Эстрогены и комбинированные оральные контрацептивы. Вопр. гинекол. акуш. перинатол. (Гинекология, акушерство и перинатология). 2020; 19(2): 118–123.Лазовцева О.Д., Мохорт Т.В. / Оценка ведения синдрома поликистозных яичников и особенности выбора комбинированного орального контрацептива // Здравоохранение (Минск). – 2022. – № 1(898). – С. 29-40. Doi: 10.20953/1726-1678-2020-2-118-123</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Оразов М.Р., Радзинскии ̆В.Е., Долгов Е.Д., Ермаков В.В. / Эндокринно-метаболические эффекты оральных контрацептивов, содержащих эстетрол и дроспиренон // Вопросы гинекологии, акушерства и перинатологии. – 2022. – Т. 21, № 4. – С. 146-151. – DOI 10.20953/17261678-2022-4-146-150.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Калиушко, А. В. Ишемический инсульт в молодом возрасте: роль факторов риска / А. В. Калиушко, О. В. Полянская // Иценковские чтения-2023 : Сборник научных трудов межрегиональной научно-практической конференции к 134-летию со дня рождения профессора Иценко Николая Михайловича, Воронеж, 24 мая 2023 года. – Воронеж: Воронежский государственный медицинский университет имени Н.Н. Бурденко, 2023. – С. 60-71.</mixed-citation></ref></ref-list></back></article>
